Text Size

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00638742
First received: March 12, 2008
Last updated: December 29, 2010
Last verified: December 2010
History of Changes
  Purpose

To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.


Condition Intervention Phase
Glaucoma
Ocular Hypertension
 Drug: latanoprost
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.

Resource links provided by NLM:

Drug Information available for: Latanoprost
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Plasma latanoprost acid concentrations at steady-state. [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse events related to systemic exposure of latanoprost [ Time Frame: 1 Day ] [ Designated as safety issue: Yes ]

Enrollment: 47
Study Start Date: May 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: latanoprost
latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.

Detailed Description:

Pharmacokinetics and Safety

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks.
  • The pediatric subjects will be grouped by age (0 to <3 years, 3 to <12 years, 12 to 18 years).

Exclusion Criteria:

  • Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit.
  • History of ocular trauma or surgery in either eye within 14-days of the screening visit.
  • Use of continuous wear contact lenses.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00638742

Locations
United States, California
Pfizer Investigational Site
Artesia, California, United States, 90701
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30339
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
United States, Massachusetts
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27705
Denmark
Pfizer Investigational Site
Koebenhavn OE, Denmark, 2100
Italy
Pfizer Investigational Site
Catania, Italy, 95123
Portugal
Pfizer Investigational Site
Coimbra, Portugal, 3000-548
Pfizer Investigational Site
Lisboa, Portugal, 1169-097
South Africa
Pfizer Investigational Site
Mayfair West, South Africa, 2109
Spain
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Madrid, Spain, 28040
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00638742     History of Changes
Other Study ID Numbers: A6111139
Study First Received: March 12, 2008
Last Updated: December 29, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Latanoprost Pediatrics Pharmacokinetics Safety

Additional relevant MeSH terms:
Glaucoma
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
 Latanoprost
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013